Giant-Cell Arteritis - Pipeline Insight, 2024

This “Giant-Cell Arteritis - Pipeline Insight, 2024,” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Giant-Cell Arteritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Giant-Cell Arteritis Understanding

Giant-Cell Arteritis: Overview

Giant cell arteritis (GCA) is the most common blood vessel disorder in persons over 50 years old that causes inflammation of medium and large-sized arteries in the body (vasculitis). GCA causes changes in blood vessel walls leading to poor blood circulation. Arteries most affected in giant cell arteritis are the temporal artery and other cranial arteries (now called cranial-GCA), but inflammation of the aorta and other large arteries in the body can occur as well and may present differently (now called large vessel-GCA). If left untreated, this can lead to a medical emergency where sudden blindness occurs without early detection and treatment. Signs and symptoms when the temporal or other cranial arteries are involved include arm pain, pulsing headaches on one side or on the back of the head, jaw pain, scalp tenderness, double vision or other visual disturbances, bulging temporal artery that is tender with skin edema and redness. It can also present with constitutional symptoms such as polymyalgia, fevers, anorexia, and weight loss, a presentation of LV-GCA. The cause of giant cell arteritis is still unknown but is thought to be from the immune system causing damage to the body’s own blood vessels. Polymyalgia rheumatica is an inflammatory disorder that is closely related to giant cell arteritis and occurs in 40% to 60% of patients with giant call arteritis. 15% to 20% of persons with polymyalgia rheumatica will have giant cell arteritis. Treatments available include steroids (corticosteroids) that will help with symptoms and reoccurrence and medications that weaken the immune system.

Giant-Cell Arteritis - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Giant-Cell Arteritis pipeline landscape is provided which includes the disease overview and Giant-Cell Arteritis treatment guidelines. The assessment part of the report embraces, in depth Giant-Cell Arteritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Giant-Cell Arteritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Giant-Cell Arteritis.
• In the coming years, the Giant-Cell Arteritis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies and academics that are working to assess challenges and seek opportunities that could influence Giant-Cell Arteritis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

• A detailed portfolio of major pharma players who are involved in fueling the Giant-Cell Arteritis treatment market. Several potential therapies for Giant-Cell Arteritis are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Giant-Cell Arteritis market size in the coming years.
• This in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Giant-Cell Arteritis) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Giant-Cell Arteritis Emerging Drugs Chapters

This segment of the Giant-Cell Arteritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Giant-Cell Arteritis Emerging Drugs

Secukinumab: Novartis Secukinumab is a fully human monoclonal IgG1/? antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis.6 By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders.5 Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015).3 It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. Currently, it is in Phase III stage of clinical trial evaluation to treat Giant CellArteritis.

Upadacitinib: AbbVie Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor used in the treatment of moderate to severe rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, and severe atopic dermatitis, including in patients who did not respond well to other therapies. The FDA approved upadacitinib in August 2019 and it is used for the treatment of active rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and ankylosing spondylitis.9 In December 2019, it was additionally approved by the European Commission.10 Upadacitinib is marketed under the brand name RINVOQ for oral administration. Currently, it is in Phase III stage of clinical trial evaluation to treat Giant CellArteritis.

Giant-Cell Arteritis: Therapeutic Assessment

This segment of the report provides insights about the different Giant-Cell Arteritis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Giant-Cell Arteritis

There are approx. 6+ key companies which are developing the therapies for Giant-Cell Arteritis. The companies which have their Giant-Cell Arteritis drug candidates in the most advanced stage, i.e. phase III include, Novartis.

Phases

This report covers around 6+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Giant-Cell Arteritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Giant-Cell Arteritis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Giant-Cell Arteritis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Giant-Cell Arteritis drugs.

Giant-Cell Arteritis Report Insights

• Giant-Cell Arteritis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Giant-Cell Arteritis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Giant-Cell Arteritis drugs?
• How many Giant-Cell Arteritis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Giant-Cell Arteritis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Giant-Cell Arteritis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Giant-Cell Arteritis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Novartis
• AbbVie
• XOMA
• Kiniksa Pharmaceuticals, Ltd.
• Eli Lilly and Company
• Janssen Biotech
• Dr Reddys Laboratories

Key Products

• Secukinumab
• Upadacitinib
• ABBV-154
• Gevokizumab
• Mavrilimumab
• Baricitinib
• Guselkumab
• DRL-TC